Last $31.82 USD
Change Today +0.55 / 1.76%
Volume 88.5K
BRLI On Other Exchanges
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

bio-reference labs inc (BRLI) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/27/14 - $34.00
52 Week Low
01/6/14 - $24.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIO-REFERENCE LABS INC (BRLI)

bio-reference labs inc (BRLI) Related Bloomberg News

View More Bloomberg News

bio-reference labs inc (BRLI) Related Businessweek News

No Related Businessweek News Found

bio-reference labs inc (BRLI) Details

Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases in New Jersey, New York, Maryland, Massachusetts, Texas, and Ohio. The company offers chemical diagnostic tests, such as blood and urine analysis; blood chemistry; hematology services; serology; radio-immuno analysis; toxicology, including drug screening; pap smears; tissue pathology comprising biopsies; and other tissue analysis, as well as cancer cytogenetic testing, genetic testing, and cytology testing services. It focuses on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional health care services. The company also operates a clinical knowledge management service unit, which uses customer data from laboratory results, pharmaceutical data, claims data, and other data sources to provide administrative and clinical decision support systems; and a Web-based connectivity portal solution for laboratories and physicians. It serves physicians, geneticists, hospitals, clinics, and correctional and other health facilities. The company was founded in 1981 and is headquartered in Elmwood Park, New Jersey.

bio-reference labs inc (BRLI) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $1.2M
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $449.2K
Chief Operating Officer, Executive Vice Presi...
Total Annual Compensation: $449.9K
Compensation as of Fiscal Year 2013.

bio-reference labs inc (BRLI) Key Developments

Bio-Reference Laboratories Not In Compliance With NASDAQ Listing Rules

On November 17, 2014, Mr. Gary Lederman, an independent member of the board of directors of Bio-Reference Laboratories, Inc., passed away. Pursuant to the rules of The Nasdaq Stock Market, the Company immediately notified Nasdaq of this event and that the Board was no longer comprised of a majority of independent directors. Following the Company’s notice to Nasdaq, on November 21, 2014, the Company received from the staff of the Listing Qualifications Department of the NASDAQ Stock Market a letter indicating that the Company was not in compliance with Listing Rule 5605(b)(1), which requires a majority of the Board of the Company be comprised of independent directors as defined in Rule 5605(a)(2). Consistent with Nasdaq Listing Rule 5605(b)(1)(A), the Staff Letter indicated that Nasdaq will provide the Company a cure period in order to regain compliance with the majority independent board requirement. Pursuant to the Staff Letter, the Company will have until the earlier of the Company’s next annual shareholders’ meeting or November 17, 2015 to regain compliance with this listing rule. However, if the Company’s next annual shareholders’ meeting is held before May 19, 2015, then the Company must evidence compliance no later than May 19, 2015. The Company shall use its best effort to regain compliance with the majority independent board requirement before the cure period ends to ensure continued listing on Nasdaq.

Bio-Reference Laboratories Inc. Presents at Credit Suisse Annual Healthcare Conference, Nov-11-2014 02:30 PM

Bio-Reference Laboratories Inc. Presents at Credit Suisse Annual Healthcare Conference, Nov-11-2014 02:30 PM. Venue: The Biltmore, 2400 E Missouri Ave, Phoenix, AZ 85016, United States. Speakers: Richard L. Faherty, Senior Vice President of Corporate Affairs, Interoperability & Communications.

The State Department of Public Health Issues Cease and Desist Order Against BioReference Laboratories Inc

The state Department of Public Health (DPH) issued a cease and desist order against BioReference Laboratories Inc. of New Jersey for operating the unlicensed blood collection centers in Fairfield, Ansonia, Milford, New London, Norwich, Waterbury, Wallingford and North Stonington. The order said BioReference has a licensed clinical laboratory at 27 Hospital Ave. in Danbury, but that it opened the other labs before receiving a license or certificate to operate them. In the order, BioReference agreed to stop operations at those locations until it obtains a license or certificate. The company, which bills itself on its website as the third large chain of full-service clinical diagnostic labs in the U.S., admitted in the order that it had operated the eight labs without a license. It also agreed that if it does not comply with the cease and desist order, that would be sufficient grounds for DPH to suspend its license to operate in Connecticut.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BRLI:US $31.82 USD +0.55

BRLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliance HealthCare Services Inc $22.33 USD -0.28
Genomic Health Inc $32.44 USD +1.32
Myriad Genetics Inc $36.50 USD +0.28
RadNet Inc $9.41 USD -0.08
Sequenom Inc $3.59 USD -0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation BRLI Industry Range
Price/Earnings 19.0x
Price/Sales 1.1x
Price/Book 2.8x
Price/Cash Flow 18.9x
TEV/Sales 1.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO-REFERENCE LABS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at